logo-loader

ReNeuron's Michael Hunt updates on product development

Published: 00:55 27 Mar 2018 AEDT

Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) chats to Proactive to update on the cell-based therapeutics specialist's research and development programmes.

Hunt says they're to increase the number of clinical sites in their PISCES III study from 25 to 40.

PISCES III is a phase IIb clinical study in the US of ReNeuron’s CTX cell therapy candidate for stroke disability.

First patient dosing in the study is expected in mid-2018 and top-line data from the study, as previously indicated, is expected in late 2019.

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18